Cu(ii)-BODIPY photosensitizer for CAIX overexpressed cancer stem cell therapy

Hyo Sung Jung, Seyoung Koo, Miae Won, Seeun An, Haebeen Park, Jonathan L. Sessler, Jiyou Han, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Chemoresistance originating from cancer stem cells (CSCs) is a major cause of cancer treatment failure and highlights the need to develop CSC-targeting therapies. Although enormous progress in both photodynamic therapy (PDT) and chemodynamic therapy (CDT) has been made in recent decades, the efficacy of these modalities against CSC remains limited. Here, we report a new generation photosensitizer, CA9-BPS-Cu(ii), a system that combines three subunits within a single molecule, namely a copper catalyst for CDT, a boron dipyrromethene photosensitizer for PDT, and acetazolamide for CSC targeting via carbonic anhydrase-9 (CA9) binding. A therapeutic effect in MDA-MB-231 cells was observed that is ascribed to elevated oxidative stress mediated by a combined CDT/PDT effect, as well as through copper-catalysed glutathione oxidation. The CSC targeting ability of CA9-BPS-Cu(ii) was evident from the enhanced affinity of CA9-BPS-Cu(ii) towards CD133-positive MDA-MB-231 cells where CA9 is overexpressed vs. CD133-negative cells. Moreover, the efficacy of CA9-BPS-Cu(ii) was successfully demonstrated in a xenograft mouse tumour model.

Original languageEnglish
Pages (from-to)1808-1819
Number of pages12
JournalChemical Science
Issue number7
Publication statusPublished - 2023 Jan 19

ASJC Scopus subject areas

  • Chemistry(all)


Dive into the research topics of 'Cu(ii)-BODIPY photosensitizer for CAIX overexpressed cancer stem cell therapy'. Together they form a unique fingerprint.

Cite this